Abstract
The p38 mitogen-activated protein (MAP) kinase plays a central role in inflammation. It has been the subject of extensive efforts in both basic research and drug discovery for the treatment of inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis, where aberrant cytokine signaling is the driver of the disease. This article reviews the patent and journal publication activities during 2006-2008 describing novel small molecule p38α inhibitors.
Keywords: mitogen-activated protein (MAP), p38, Kinase Inhibitors, inflammation, rheumatoid arthritis, cytokine, bowel disease
Current Topics in Medicinal Chemistry
Title: Small Molecule p38 MAP Kinase Inhibitors for the Treatment of Inflammatory Diseases: Novel Structures and Developments During 2006- 2008
Volume: 8 Issue: 16
Author(s): Liping H. Pettus and Ryan P. Wurz
Affiliation:
Keywords: mitogen-activated protein (MAP), p38, Kinase Inhibitors, inflammation, rheumatoid arthritis, cytokine, bowel disease
Abstract: The p38 mitogen-activated protein (MAP) kinase plays a central role in inflammation. It has been the subject of extensive efforts in both basic research and drug discovery for the treatment of inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis, where aberrant cytokine signaling is the driver of the disease. This article reviews the patent and journal publication activities during 2006-2008 describing novel small molecule p38α inhibitors.
Export Options
About this article
Cite this article as:
Pettus H. Liping and Wurz P. Ryan, Small Molecule p38 MAP Kinase Inhibitors for the Treatment of Inflammatory Diseases: Novel Structures and Developments During 2006- 2008, Current Topics in Medicinal Chemistry 2008; 8 (16) . https://dx.doi.org/10.2174/156802608786264245
DOI https://dx.doi.org/10.2174/156802608786264245 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Endocrinology and Immunology of Obesity, Obesity Vaccines
Current Clinical Pharmacology Chromogranin A and the Endothelial Barrier Function
Current Medicinal Chemistry Progress in Studies of Structure, Mechanism and Antagonists Interaction of GPCR Co-Receptors for HIV
Current Pharmaceutical Biotechnology Study of Intercellular Adhesion Molecule-1 (ICAM-1) in Bone Homeostasis
Current Drug Targets Clinical Pharmacology of Cyclophosphamide and Ifosfamide
Current Drug Therapy Prolyl-Specific Peptidases and Their Inhibitors in Biological Processes
Current Chemical Biology The Evolution of Schizophrenia: A Model for Selection by Infection, with a Focus on NAD
Current Pharmaceutical Design Protein Kinase C-theta Inhibitors: A Novel Therapy for Inflammatory Disorders
Current Pharmaceutical Design Selective Removal of Macrophages in Atherosclerotic Plaques as a Pharmacological Approach for Plaque Stabilization: Benefits Vs. Potential Complications
Current Vascular Pharmacology Anti-inflammatory strategies in stroke: a potential therapeutic target
Current Vascular Pharmacology Update on the Rheumatologic Manifestations of Malignancy
Current Cancer Therapy Reviews Polymeric Carriers for Gene Delivery: Chitosan and Poly(amidoamine) Dendrimers
Current Pharmaceutical Design Ocular Inflammatory Diseases: Molecular Pathogenesis and Immunotherapy
Current Molecular Medicine Recent Advances in the Synthesis and Development of Curcumin, its Combinations and Formulations and Curcumin-like Compounds as Anti-infective Agents
Current Medicinal Chemistry Editorial (Thematic issue: Discovering New Anticancer Activities from Old Drugs)
Current Medicinal Chemistry Chlorophytum borivilianum: A White Gold for Biopharmaceuticals and Neutraceuticals
Current Pharmaceutical Biotechnology New Pharmacological Perspectives and Therapeutic Potential of PPAR-γ Agonists
Current Pharmaceutical Design Progress of Biological Agents on Psoriatic Arthritis
Current Pharmaceutical Biotechnology Anti-Interleukin-6 Receptor Antibody Therapy in Rheumatic Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Dihidro-β-Agarofuran Sesquiterpenes: A New Class of Reversal Agents of the Multidrug Resistance Phenotype Mediated by P-Glycoprotein in the Protozoan Parasite Leishmania
Current Pharmaceutical Design